10-11-24: Went to House’s Money 7 months. Not perfect, but not bad. Fingers cross for the remaining shares to help me retire.
04-12-24: Again, worried about hopeful thinking here, but they are profitable with a debt/equity of 0.98% and book value is triple the current price. I’m going in again.
03-23-24: Maybe it is a sunk-cost fallacy that has me holding, or maybe I am reading this PR right in that someone with experience in these issues has a way forward that could make me feel better about this itchy trigger finger holding: https://finance.yahoo.com/news/amylyx-pharmaceuticals-appoints-bernhardt-zeiher-130000641.html
03-09-24: Another one of my dumpster-diving acquisitions. It’s not so much about market timing as it is about market reverse-anthropomorphizing where there are times the market that is racing and winning gets skittish around anything that is even slightly out of the ordinary. In this case, a failed patient trial for a company that still has a lot of cash and is hiring for multiple positions. The next step is to hope for either a dead-cat-bounce or actual turn-around to bring it up enough to sell half to recoup the original investment and ride out the rest.
Full disclosure: These types of trades require sub-optimal evaluations and my take on the bad news to killed the price did not discover that they are considering a recall.
OTOH…there were no ill effects reported and generally something that gets all the way to clinical trial has some benefit that can be salvaged. So, fingers-crossed and this is also why I don’t sink a lot into these gambles ($285 in this case)